BNGO Bionano Genomics
- 0.9565
- -0.0400-4.01%
Bionano Genomics News
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the RBC C
Bionano Announces Publication Showing OGM's High Resolution Structural Variation Detection In Cancer Validated By Cas9-Directed Nanopore Sequencing
Bionano Genomics, Inc. (NASDAQ:BNGO), today announced the results of an implementation study conducted by researchers at University Medical Center Groningen that compared optical genome mapping (OGM)
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health
Bionano Genomics (BNGO) said Wednesday it has entered into an original equipment manufacturing partnership with Hangzhou Diagens Biotechnology to commercialize cytogenetic workflow to support reproduc
Bionano Enters OEM Partnership With Diagens To Commercialize A Clinical Cytogenetic Analysis That Combines OGM And Artificial Intelligence
Bionano Enters OEM Partnership With Diagens To Commercialize A Clinical Cytogenetic Analysis That Combines OGM And Artificial Intelligence
Bionano Announces Publication Showing That OGM Detects Over 1250 Structural Variants, Including 56 Gene Fusions, In Pediatric Leukemia That Were Missed By Whole Genome Sequencing
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study from Penn State College of Medicine that used optical genome mapping (OGM) to search for clinically and biologically rel
BioNano Genomics Launches Offering to Bolster Finances
Bionano Genomics Expects $10M in Proceeds From Direct Offering
By Denny Jacob Bionano Genomics agreed to the purchase and sale of its common stock. The San Diego genome analysis solutions provider will purchase and sell about 8.7 million shares and warrants to
Bionano Announces $10M Registered Direct Offering At $1.02/Share
Bionano Announces $10M Registered Direct Offering At $1.02/Share
Bionano Published Study Showing That OGM Identifies Genetic Aberrations In Sarcoma Samples That May Lead To Improved Diagnosis But Were Missed By Classical Cytogenetics
Bionano Published Study Showing That OGM Identifies Genetic Aberrations In Sarcoma Samples That May Lead To Improved Diagnosis But Were Missed By Classical Cytogenetics
Bionano Announces 9 Poster Presentations and Introduces New High Throughput Stratys System at the American Association for Cancer Research Annual Meeting
Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid tumors, and applications in cell and gene t
Bionano Announces Publication Of A Breast Cancer Study Showing That The Number Of SVs Detected With OGM May Be Related To Prognosis, Tumor Progression And Chemotherapy Resistance
Bionano Genomics, Inc. (NASDAQ:BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibit
Bionano Announces Publication of a Breast Cancer Study Showing That the Number of SVs Detected With OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer
BioNano Genomics (BNGO) Gets a Hold From Maxim Group
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2023 Earnings Call Transcript
Bionano Genomics Is Maintained at Sector Outperform by Scotiabank
Bionano Genomics Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains Sector Outperform on Bionano Genomics, Lowers Price Target to $6
Scotiabank analyst Sung Ji Nam maintains Bionano Genomics with a Sector Outperform and lowers the price target from $7 to $6.
Bionano Genomics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 395.87% Scotiabank $7 → $6 Maintains Sector Outperform 11/13/2023 — Maxim Group Downgrades Buy
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company's New Stratys System
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2024.
A New Cause for Concern: Bionano Genomics Adds a New Share Price & Shareholder Rights Risk
Analysis
Price Target
No Data
